Focussing on the Stock with Outstanding Half-Yearly Performance: $ADAP $ALPN $SURF

The Market Signal was created as a platform to help investors, if you own (NASDAQ:ADAP), (NYSE:ALPN) or (NASDAQ:SURF) and want to join the fastest growing community of investors on the web then sign up to the link below. Members get free access to the best investment tools in the world. Start trading like a pro today. This is a limited time offer so click the link below NOW.

https://themarketsignal.com/Free-Report/NOW

(Click link above or copy, paste and hit enter in your browser for your report)

Adaptimmune Therapeutics provides details about its Phase 1 trial

https://themarketsignal.com/Free-Report/ADAP

(Click link above or copy, paste and hit enter in your browser for your report)

The performance of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) over the past six months rose by a margin of 124.07%. This company unveiled data from its Phase 1 trial that involved SPEAR T-cells.

It was during the virtual International Liver Congress (ILC) that the company announced these results. Patients with hepatocellular carcinoma (HCC) were studied, with the company reporting an impressive safety profile. As per the time of the data cutoff, only nine patients had received treatment. The first two dose cohorts were used in the treatment of about five patients. The study used doses of 100 million and 1 billion and it was impressive that the patients in question showed outstanding responses. Those were doses of transduced cells to be specific.

Alpine Immune Sciences enters a licensing agreement

https://themarketsignal.com/Free-Report/ALPN

(Click link above or copy, paste and hit enter in your browser for your report)

The past six months have witnessed the stock of Alpine Immune Sciences Inc. (NASDAQ:ALPN) rise by a margin of 124.31%.

Key Second Quarter 2020 and Subsequent Highlights

AbbVie and Alpine pronounced an ALPN-101 license The terms of the deal provide that Alpine receives about $60 millionin upfront payment. Asides from that, it will be entitled to receive $805 million for the regulatory, success-based development, and commercial milestones achieved. The tiered royalties on net sales of ALPN-101 is the other privilege that Alpine gets to benefit from. On the other hand, AbbVie was entitled to an exclusive license for ALPN-101. Alpine is pleased to pronounce the syccesful dosing of its first patient in the NEON-1 Phase 1 study of ALPN-202. The target was to discover a way to handle the advanced malignancies. About $60 Millionwas raised by the company, an amount obtained from private placement gross proceeds. Omega Funds , Samsara BioCapital, and Avidity Partners were some of those that participated in the private placement. Alpine intends to utilize the net proceeds in financing the general corporate purposes as well as in the development of its clinical and preclinical pipeline.

Surface Oncology enters a clinical trial collaboration

https://themarketsignal.com/Free-Report/SURF

(Click link above or copy, paste and hit enter in your browser for your report)
The performance of Surface Oncology Inc. (NASDAQ:SURF) over the past six months shot up by margin of 124.56%.

Recent Corporate Highlights:

The Phase 1 clinical trial started in April and it involved SRF388 which happens to be the company's first-in-class antibody. This was a product targeting the immunosuppressive cytokine IL-27. The clinical trial collaboration involving the company and with Merck (NYSE: MRK) was about evaluating the efficacy and safety of Surface's SRF617 combined with Merck's KEYTRUDA(R)(pembrolizumab).Patients struggling with solid tumors and gastric cancer are the ones under focus by the study.

Please email or contact us for any edits or errors relating to this stock market news.

If you would like information on using our press release distribution service aimed at helping investors with the best stocks to buy and how to create your own stock portfolio. We cover the US Stock Market, Canadian Stock Market, the Australian Stock Market and other Stock Market news.

We will get back to you within 24 hours.

Disclaimer

comtex tracking

COMTEX_370980251/2705/2020-09-09T06:31:56

Is there a problem with this press release? Contact the source provider Comtex at editorialpr@comtex.com.